Article ID Journal Published Year Pages File Type
2159234 Radiotherapy and Oncology 2010 5 Pages PDF
Abstract

PurposeTo retrospectively assess the physics contributions and the clinical outcome with preliminary 3D MRI-guided low dose-rate (LDR) intracavitary brachytherapy (BT) experience in locally advanced cervical cancer patients.Patients and methodsEighty-four patients with primary locally advanced cervical carcinoma were analyzed. The median tumoral cervical volume was 48.0 cc (range 1–468 cc). Twenty-four patients (53%) had histological and/or radiological pelvic involvement. After pelvic ± paraaortic concomitant chemoradiation, a LDR BT boost was delivered to a 3D MRI-based clinical target volume taking into account dose volume constraints for critical organs and optimization of target volume coverage.ResultsWith a median follow-up of 53 months (range 31–79 months), the 4-year overall survival and disease-free survival rates were 57 (95%CI, 43–69) and 52% (95%CI, 40–64), respectively. Adding EBRT and LDR using EQD2 model, the median D100 and D90 for the IR-CTV were 56.5 Gyα/β10 (range 37–83 Gyα/β10) and 69 Gyα/β10 (range 52–113 Gyα/β10), respectively. For HR-CTV, the median D100 and D90 were 67 Gyα/β10 (range 47–119 Gyα/β10) and 79 Gyα/β10 (range 53–122 Gyα/β10), respectively. Thirty-nine late complications were observed in 28 patients (33.3%): 13 bladder, 7 rectal, 5 small bowel, 4 urethral, 3 colic, 2 vaginal, 1 pelvic fibrosis, and 4 others. Four grade 3 delayed complications were observed and no grade 4 complication occurred.ConclusionsApplying an individual treatment planning with 3D MRI-guided LDR brachytherapy appears to be feasible and efficient for patients with locally advanced cervical cancer in routine clinical practice.

Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Cancer Research
Authors
, , , , , ,